How many drugs treat Epidermolysis bullosa?

Drug Landscape tracks 3 marketed treatments for Epidermolysis bullosa (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/epidermolysis-bullosa.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Epidermolysis bullosa — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Epidermolysis bullosa (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Epidermolysis bullosa, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target
Filsuvez	birch bark extract	Amryt Pharmaceuticals Dac
Filsuvez	Filsuvez	Amryt Pharma
Filsuvez	garadacimab	CSL Behring	Anti-Factor XIIa monoclonal antibody	Activated Factor XII (FXIIa)

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Amryt Pharma · 1 drug in Epidermolysis bullosa
Amryt Pharmaceuticals Dac · 1 drug in Epidermolysis bullosa
CSL Behring · 1 drug in Epidermolysis bullosa

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Epidermolysis bullosa:

Cite this brief

Drug Landscape (2026). Epidermolysis bullosa — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/epidermolysis-bullosa. Accessed 2026-06-10.

Epidermolysis bullosa full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing